Aclarion partners with Scripps Health for Nociscan technology, retail traders optimistic

From Stocktwits: 2025-03-03 23:52:14

Aclarion Inc.’s (ACON) stock surged by nearly 127% following a commercial agreement with Scripps Health to bring its Nociscan technology to doctors in San Diego. The deal allows physicians to personalize treatment for chronic lower back pain using advanced technology. Retail traders responded enthusiastically, driving a surge in trading activity and online discussions. Stocktwits polls show mixed opinions on the partnership, with some suggesting Aclarion could be an acquisition target for major medical technology firms. Short interest on the stock has increased significantly, with the stock up over 5% year-to-date. Analyst coverage on Aclarion is limited, with one ‘Buy’ and one ‘Hold’ rating.



Read more at Stocktwits: Is Aclarion’s Tie-Up With Scripps Health A Lasting Catalyst? Most Retail Traders Think It’s A ‘Game-Changer’